This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Europe: Oligonucleotide and Peptide Therapeutics

SAVINGS DEADLINE EXPIRES:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
Delivered as Hybrid Event from 16-18 November 2022
Live In-Person Conference Delivered 16-18 NovemberAustria Center Vienna

Norbert Pardi, PhD
Research Assistant Professor of Medicine at University of Pennsylvania

Profile

Dr. Norbert Pardi holds a Ph.D. in biochemistry and genetics. He has been working at the University of Pennsylvania since 2011 and currently holds an Assistant Professor position at the Department of Microbiology of the Perelman School of Medicine. His research interest is the development of mRNA-based therapeutics with particular focus on new generation vaccines. He explored the development of a novel vaccine platform using nucleoside-modified mRNA in lipid nanoparticles (LNPs) and used it to generate highly effective vaccines targeting various pathogens. Dr. Pardi is a pioneer of the nucleoside-modified mRNA vaccine technology and published milestone papers in the field.

Agenda Sessions

  • Development of Broadly Protective Influenza Vaccines Using Necleoside-Modified mRNA

    08:15